The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On July 7, Kailera Therapeutics announced that its GLP-1 drug for diabetes and obesity met the primary endpoints in two late-stage trials. On the same day, the U.S. Food and Drug Administration approved Vera Therapeutics' drug to treat a potentially life-threatening kidney disease. On July 9, Dr. Reddy's Laboratories announced a delay in commercial supplies of semaglutide due to an issue with the active pharmaceutical ingredient.